Early Access

Early access to Acerta Pharma investigational medicinal products

We recognize that there are circumstances where patients with serious or life-threatening diseases have exhausted all available therapeutic options and may not be eligible to enroll in one of our clinical trials. In such circumstances individual patients may be eligible for early access to an Acerta investigational medicinal product. Acerta Pharma reviews requests following principles aligned with AstraZeneca.